Andrić, Zoran

Tip

Godina

89 2000 - 2027

Mp-kat.

Godina - raspon

Godina od:

Godina do:

Rezultati 41-60 od 89 Rezultati/stranica

Godina	Naslov	Autor(i)	Tip rezultata	Mp-kat.
2021	Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA)	Trukhin, Dmytro; ...; Andric, Zoran G ; ...; (broj, koautora 19)	Naučni članak	21aM21a - Vodeći međunarodni časopis kategorije M21a
2021	Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC)	Syrigos, Konstantinos; Abert, Istvan; Andric, Zoran G ; Bondarenko, Igor N; Dvorkin, Mikhail; Galic, Kristina; Galiulin, Rinat; Kuchava, Vladimer; Sriuranpong, Virote; Trukhin, Dmytro; Zhavrid, Edvard; Fu, Dongyue; Kassalow, Laurent M; Jones, Stephanie; Bashir, Zahid;	Naučni članak	21aM21a - Vodeći međunarodni časopis kategorije M21a
2021	Polycystic Ovary Syndrome: A Contemporary Clinical Approach	Bjekić-Macut, Jelica ; Vukašin, Tamara; Velija-Ašimi, Zelija; Bureković, Azra; Zdravković, Marija ; Andrić, Zoran ; Branković, Marija ; Crevar-Marinović, Slobodanka; Mandić, Tatjana; Stanojlović, Olivera ; Vojnović-Milutinović, Danijela ; Livadas, Sarantis; Mastorakos, George;	Naučni članak	22M22 - Međunarodni časopis kategorije M22
2021	A phase Ib/II study of the dual MDMX/MDM2 inhibitor, ALRN-6924, for the prevention of chemotherapy-induced myelosuppression	Andric, Zoran G ; Ceric, Timur; Rancic, Milan H ; Jakopovic, Marko; Aix, S Ponce; Ramlau, Rodryg; Ulanska, M; Caldwell, C; Ferrari, D; Annis, A; Vukovic, V; Zaric, Bojan ;	Konferencijski rad	Mp kategorija će biti prikazana naknadno.
2021	HERIZON: Phase 2 part of the IMU-131 HER2/neu vaccine plus chemotherapy study randomized in patients with HER2/NEU overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction	Maglakelidze, Marina; ...; Andric, Zoran G ; Nikolic, Ivan V ; ...; Radosavljevic, Davorin Z ; Petrovic, Zeljko M; ...; (broj, koautora 16)	Konferencijski rad	Mp kategorija će biti prikazana naknadno.
2021	IMpower110: Updated OS Analysis of Atezolizumab vs Platinum-Based Chemotherapy as First-Line Treatment in PD-L1-Selected NSCLC	Herbst, Roy S; ...; Andric, Zoran G ; ...; (broj, koautora 20)	Konferencijski rad	Mp kategorija će biti prikazana naknadno.
2021	Atezolizumab (atezo) vs platinum-based chemo in blood-based tumour mutational burden-positive (bTMB plus ) patients (pts) with first-line (1L) advanced/metastatic (m)NSCLC: Results of the Blood First Assay Screening Trial (BFAST) phase III cohort C	Dziadziuszko, R; ...; Andric, Zoran G ; ...; (broj, koautora 20)	Konferencijski rad	Mp kategorija će biti prikazana naknadno.
2021	Bevacizumab biosimilar (MB02) and reference bevacizumab in patients with stage IIIB/IV non-squamous non-small cell lung cancer (NSCLC) (STELLA study): Multiple Imputation analysis.	Trukhin, Dmytro; Poddubskaya, Elena; Andric, Zoran G ; Bondarenko, Igor N; Shevnia, Serhii; Zaric, Bojan ; Bellala, Ravishankar; Charoentum, Chaiyut; Perez, Luis; Bullo, Felicitas; Garcia, Fernanda;	Konferencijski rad	Mp kategorija će biti prikazana naknadno.
2021	Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies	Weiss, Jared; Goldschmidt, Jerome; Andric, Zoran G ; Dragnev, Konstantin H; Gwaltney, Chad; Skaltsa, Konstantina; Pritchett, Yili; Antal, Joyce M; Morris, Shannon R; Daniel, Davey	Naučni članak	21M21 - Vodeći međunarodni časopis kategorije M21
2020	Impower110: Interim OS Analysis of a Phase III Study Of Atezolizumab (ATEZO) vs Platinum-Based Chemotherapy (Chemo) as 1L Treatment (TX) in PD-L1-Selected NSCLC	Reinmuth, Niels; ...; Andric, Zoran G ; ...; (broj, koautora 20)	Konferencijski rad	Mp kategorija će biti prikazana naknadno.
2020	Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, PlaceboControlled Phase II Study	Hart Lowel L; Ferrarotto Renata; Andrić Zoran G ; Beck Thaddeus J; Subramanian Janakiraman; Radosavljević Davorin Z ; Zarić Bojan ; Hanna Wahid T; Aljumaily Raid; Owonikoko Taofeek K; Verhoeven Didier; Xiao Jie; Morris Shannon R; Antal Joyce M; Hussein Maen A;	Naučni članak	21M21 - Vodeći međunarodni časopis kategorije M21
2020	Hypertension in Polycystic Ovary Syndrome: Novel Insights	Macut, Đuro ; Mladenović, Violeta ; Bjekić-Macut, Jelica ; Livadas, Sarantis; Stanojlović, Olivera ; Hrnčić, Dragan ; Rašić-Marković, Aleksandra ; Vojnović-Milutinović, Danijela ; Andrić, Zoran	Naučni članak	23M23 - Međunarodni časopis kategorije M23
2020	Impower110: Interim Overall Survival (OS) Analysis of a Phase Iii Study of Atezolizumab (Atezo) Monotherapy Vs Platinum-Based Chemotherapy (Chemo) as First-Line (1L) Treatment in PD-L1-Selected NSCLC	Herbst, Roy S; ...; Andric, Zoran G ; ...; (broj, koautora 20)	Konferencijski rad	Mp kategorija će biti prikazana naknadno.
2020	Bevacizumab biosimilar and reference bevacizumab in subjects with stage IIIB/IV no squamous non-small cell lung cancer (NSCLC) (STELLA study): Results for the primary endpoint in a confirmatory, double-blind, randomized, controlled study.	Millan, Susana; Trukhin, Dmytro; Kolesnik, Oleksii; Poddubskaya, Elena; Andric, Zoran G ; Bondarenko, Igor N; Shevnia, Serhii; Bullo, Felicitas; Sarnago, Cristina	Konferencijski rad	Mp kategorija će biti prikazana naknadno.
2020	Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial	Mansfield, AS; ...; Andric, Zoran G ; ...; (broj, koautora 19)	Naučni članak	21a+M21a+ - Vodeći međunarodni časopis kategorije M21a+
2020	Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC	Herbst, Roy S; ...; Andric, Zoran G ; ...; (broj, koautora 22)	Naučni članak	21a+M21a+ - Vodeći međunarodni časopis kategorije M21a+
2020	Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by PD-L1 immunohistochemistry (IHC) assays and blood tumour mutational burden (bTMB): IMpower110	Herbst, Roy S; ...; Andric, Zoran G ; ...; (broj, koautora 21)	Konferencijski rad	Mp kategorija će biti prikazana naknadno.
2020	Myelopreservation and reduced use of supportive care with trilaciclib in patients with small cell lung cancer.	Jared, Weiss; Jerome, Goldschmidt; Andric, Zoran G ; Konstantin, Dragnev H; Yili, Pritchett; Shannon, Morris R; Rajesh, Malik K; Davey, Daniel B	Konferencijski rad	Mp kategorija će biti prikazana naknadno.
2020	Prevention of Chemotherapy-induced Myelosuppression in SCLC patients treated with the Dual MDMX/MDM2 Inhibitor ALRN-6924	Andric, Zoran G ; Ceric, Timur; Stanetic, Mirko; Rancic, Milan H ; Jakopovic, Marko; Aix, S Ponce; Ramlau, Rodryg; Smit, E; Ulanska, M; Caldwell, C; Ferrari, D; Annis, A; Vukovic, V; Zaric, Bojan ;	Konferencijski rad	Mp kategorija će biti prikazana naknadno.
2019	IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1-selected NSCLC	Spigel, D; ...; Andric, Zoran G ; ...; (broj, koautora 20)	Konferencijski rad	Mp kategorija će biti prikazana naknadno.